• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is STAAR Surgical (STAA) A Bargain Following Its Profit Turnaround And China Led Sales Rebound?

    Simply Wall St·09/15/2026 08:23:36
    Listen to the news

    Why STAAR Surgical Is Back On Investors’ Radar

    STAAR Surgical (STAA) has drawn fresh attention after quarterly net sales rose 111% year over year to US$93.5 million, flipping a prior loss into US$8.1 million in net income.

    China did much of the heavy lifting, with sales there more than doubling to US$52.3 million and contributing over half of total revenue, while new leadership appointments are reshaping how this rebound might be managed.

    The share price reaction has been more muted than the headline numbers suggest, with a 1-day share price return of 1.81% and a 30-day share price return down 11.88% as STAAR Surgical absorbed the earnings rebound and leadership reshuffle. Over a longer stretch, total shareholder return has declined 16.62% over the past year and 45.08% over three years. Recent buying interest around US$23.07 looks more like early rebuilding of confidence than a full reset of the story.

    Spot similar rebound stories and compare STAAR Surgical against other medical stocks showing sharp fundamental shifts using the curated 15 high quality undiscovered gems.

    STAAR Surgical has bounced on the earnings surprise while the longer track record still looks rough. Do you lean into the rebound now, or wait to see what the new leadership and fresh profits are worth on the numbers?

    Most Popular Narrative: 22% Undervalued

    STAAR Surgical last closed at $23.07 while the most followed narrative pegs fair value near $29.67. This puts the focus squarely on whether that implied upside is justified by China, margin work and balance sheet strength.

    STAAR Surgical has significant cash reserves and no debt, providing a strong financial base to navigate the current challenges, reduce production outputs temporarily, and invest selectively in growth initiatives, potentially stabilizing earnings and providing upside if conditions improve.

    See why 6 investors see STAAR Surgical as 22% undervalued.

    Result: Fair Value of $29.67 (UNDERVALUED)

    Still, the STAAR Surgical narrative could be knocked off course if weak consumer confidence in China lingers or if competitive pressure there becomes more intense than expected.

    Find out about the key risks to this STAAR Surgical narrative.

    Next Steps

    Feeling torn between the rebound story and the scars on STAAR Surgical’s track record is normal, so move quickly to review the numbers, weigh the evidence on both sides, and see how the balance of risks and potential upsides looks through 3 key rewards and 1 important warning sign.

    Want More Ideas Beyond STAAR Surgical?

    Do not stop at STAAR Surgical when the wider market is full of potential ideas. Use the Simply Wall St screener to quickly surface fresh opportunities that fit your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.